-
COVID-19 Messaging for Vaccination
Recruiting
More
This study will distribute videos of health professionals encouraging Covid-19 vaccination to
a large sample of Facebook users, and will test the most effective ways to maximize diffusion
of this vaccine-related content to increase vaccination rates. The study sample will be U.S.
states where vaccination rates remained low in fall 2021. The experimental design is an RCT
with 4 groups, randomized at the county level: 1) a control group which receives no
intervention, 2) a treatment group in which Facebook users receive ads which include videos
of health professionals telling them to get vaccinated, 3) a treatment group in which
Facebook users receive ads which include videos of health professionals encouraging them to
help their friends to get vaccinated, and 4) a treatment group in which Facebook users
receive ads which include videos of health professionals encouraging them to get their most
influential friends to help their friends get vaccinated. In treatments 3 and 4, participants
will have the option to sign up to be a "vaccine ambassador," in which case they will get
notifications when the study team posts new vaccine-related content, and will receive
reminders about encouraging their friends to be vaccinated. The vaccine ambassadors will also
be entered into a lottery to win prizes. The study team is building a website to host the
videos of health professionals which answer common questions about Covid-19 vaccination. The
investigators will measure engagement with the vaccine-related content as well as assess
effects on vaccination rates at the county level.
Stanford Investigators
View full details
-
Combination Chemotherapy Plus Low-Dose Radiation Therapy in Treating Patients With Stage I or Stage IIA Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
Combining chemotherapy with radiation therapy may kill more tumor cells.
PURPOSE: This phase 2 trial is studying how well giving combination chemotherapy together
with low-dose radiation therapy works in treating patients with stage I or stage IIA
Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Anne Wiley, 6507256432.
Lead Sponsor
Stanford Investigators
View full details
-
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Not Recruiting
More
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
that the median age at diagnosis is 55-60 years and frequently present compromised skin in
these patients, which increases the risk of infection. Therefore, we propose a clinical study
with allogeneic hematopoietic stem cell transplantation (HSCT) using a unique
non-myeloablative preparative regimen, TLI/ATG, to treat advanced mycosis fungoides/Sezary
syndrome (MF/SS).
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Chin, 650-721-4183.
Lead Sponsor
Stanford Investigators
View full details
-
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001
Not Recruiting
More
This study will enroll subjects with either Peripheral T-Cell Lymphoma (PTCL) or Cutaneous
T-Cell Lymphoma(CTCL),including mycosis fungoides (MF) and Sezary Syndrome (SS), who have
relapsed after achieving a complete response in study, KW-0761-001.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cutaneous Lymphoma Coordinator, 6504216370.
Stanford Investigators
View full details
-
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Not Recruiting
More
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an
investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically
mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options,
the treatments are associated with short response duration, thus this condition is largely
incurable. This investigational drug may offer less toxicity than standard treatments and
have better tumor specific targeting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kokil Bakshi, 650-421-6370.
Stanford Investigators
View full details
-
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs.
Recruiting
More
The Stanford Medical Center Program in Multi-Organ Transplantation and the Division of Bone
marrow Transplantation are enrolling patients into a research study to determine if donor
stem cells given after a living related one Haplotype match kidney transplantation will
change the immune system such that immunosuppressive drugs can be completely withdrawn.
Stanford Investigators
View full details
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Not Recruiting
More
The purpose of this trial is to develop an alternative treatment for patients with poor risk
non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem
cell transplant using the patient's own cells. This is followed with non-myeloablative
transplant using stem cells from a related or unrelated donor to try and generate an
anti-lymphoma response from the new immune system.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Not Recruiting
More
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride, bleomycin sulfate,
vinblastine, dacarbazine, cyclophosphamide, etoposide, procarbazine hydrochloride,
vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer
cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses
high-energy x rays to kill cancer cells. Giving combination chemotherapy together with
radiation therapy may kill more cancer cells. Comparing results of imaging procedures, such
as PET scans and CT scans, done before, during, and after chemotherapy may help doctors
predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase II clinical trial studies how well chemotherapy based on PET/CT scan
works in treating patients with stage I or stage II Hodgkin lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Pitsiouni, 6507216977.
Stanford Investigators
View full details
-
TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas
Not Recruiting
More
This phase I trial studies the side effects and best dose of the anti-OX40 antibody
BMS-986178 when given together with the TLR9 agonist SD-101 and radiation therapy in treating
patients with low-grade B-cell Non-Hodgkin lymphomas. TLR9 agonist SD-101 may stimulate the
immune system in different ways and stop cancer cells from growing. Anti-OX40 antibody is a
monoclonal antibody that enhances the activation of T cells, immune cells that are important
for fighting tumors Radiation therapy uses high energy x-rays to kill cancer cells and may
make them more easily detected by the immune system. Giving TLR9 agonist SD-101 together with
anti-OX40 antibody BMS 986178 and radiation therapy may work better in treating patients with
low-grade B-cell non-hodgkin lymphomas.
Stanford is currently not accepting patients for this trial.
For more information, please contact Destiny Phillips, 650-498-1313.
Stanford Investigators
View full details
-
Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides
Not Recruiting
More
To examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray
(TSEBT 12 Gy) in patients who have mycosis fungoides (MF) staged as IB to IIIA.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cameron Harrison, 6507217186.
Lead Sponsor
Stanford Investigators
View full details
-
Inducing Graft Tolerance in HLA Haplotype Matched Related and 3 Ag Matched Unrelated Living Donor Kidney Transplantation
Recruiting
More
This research study is to determine if donor blood stem cells given after living, related,
HLA antigen (Ag) haplotype match or living, unrelated donor kidney transplantation. Minimal
HLA antigen matching will include matching of 2 HLA antigens that can be either HLA A, B, and
/or DR. This research will change the immune system such that immunosuppressive drugs can be
completely withdrawn or reduced to minimal dose without kidney rejection.
Stanford Investigators
View full details
-
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma
Not Recruiting
More
This is an open label, randomized phase II study designed to evaluate the tolerability and
response rate of high-dose and low-dose regimens in patients with advanced cutaneous T-cell
lymphoma (CTCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Daniel Navi, 6507362300.
Stanford Investigators
View full details
-
Safety, Pharmacodynamics (PD), Pharmacokinetics (PK) Study of SHP141 in 1A, 1B, or 2A Cutaneous T-Cell Lymphoma (CTCL)
Not Recruiting
More
The purpose of this study is to investigate the safety and tolerability of topical SHP141
applied directly to skin lesions in patients with Stage IA, IB, or IIA Cutaneous T-cell
Lymphoma. This study will also investigate the effect of SHP141 on skin lesions in patients
with Stage IA, IB, or IIA CTCL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Illisha Rajasansi, 650-421-1397.
Stanford Investigators
View full details
-
A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma
Not Recruiting
More
The purpose of the study is to determine the efficacy and safety of enzastaurin in
participants with Cutaneous T-Cell Lymphoma (CTCL) who failed prior therapies.
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
-
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A
Not Recruiting
More
The study objective is to demonstrate that the UVADEX® Sterile Solution formulation of
methoxsalen used in conjunction with the UVAR XTS Photopheresis System can have a clinical
effect on the skin manifestations of CTCL (mycosis fungoides) in early stage disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
-
Safety Study to Evaluate Monoclonal Antibody KW-0761 in Subjects With Peripheral T-cell Lymphoma
Not Recruiting
More
This study will determine the maximum dose of KW-0761 administered intravenously that can be
given safely in subjects with previously treated peripheral T-cell lymphoma (PTCL) or
cutaneous T-cell lymphoma(CTCL)and will see if it is effective in treating the disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Katie Turner, 6507251202.
Stanford Investigators
View full details
-
Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD
Not Recruiting
More
To determine if rituximab administered after allogeneic transplantation decreases the
incidence of chronic graft-vs-host disease (cGvHD)
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Lead Sponsor
Stanford Investigators
View full details
-
Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma
Not Recruiting
More
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different
ways. Some find cancer cells and help kill them or carry cancer-killing substances to them.
Others interfere with the ability of cancer cells to grow and spread. Drugs used in
chemotherapy, such as bendamustine hydrochloride, also work in different ways to kill cancer
cells or stop them from dividing. Bortezomib may stop the growth of cancer cells by blocking
some of the enzymes needed for cell growth. Lenalidomide may stop the growth of mantle cell
lymphoma by blocking blood flow to the cancer. It is not yet known whether giving rituximab
together with bendamustine and bortezomib is more effective than rituximab and bendamustine,
followed by rituximab alone or with lenalidomide in treating mantle cell lymphoma.
PURPOSE: This randomized phase II trial studies rituximab, bortezomib, bendamustine, and
lenalidomide in treating previously untreated older patients with mantle cell lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ekaterina Dib, 650-723-0503.
Stanford Investigators
View full details
-
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Not Recruiting
More
To evaluate the efficacy and safety of topical application of MCH 0.04% in a propylene glycol
ointment (PG)in patients with stage I or IIA MF previously treated with MCH 0.02% in a PG or
AP ointment who did not achieve a complete response.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kokil Bakshi, 6504216370.
Stanford Investigators
View full details
-
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Not Recruiting
More
To measure how frequently and to what degree a complication of transplant cell acute graft
versus host disease (GvHD) occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Allogeneic Transplantation From Related Haploidentical Donors
Not Recruiting
More
The purpose of the study is to evaluate the feasibility and safety of transplanting CD34+
selected hematopoietic cells from a haploidentical related donor following a nonmyeloablative
regimen of total lymphoid irradiation (TLI) and antithymocyte globulin (ATG).
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome
Not Recruiting
More
The purpose of this study is to determine the efficacy of the drug, HuMax-CD4, in patients
with mycosis fungoides(MF) and sezary syndrome who are intolerant to or do not respond to
treatment with Targretin® and one other standard therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Daniel Navi, 6507362300.
Stanford Investigators
View full details
-
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
Not Recruiting
More
The purpose of this study is to determine if vorinostat combined with low-dose total skin
electron beam therapy (TSEBT) offers superior clinical benefit (efficacy & safety) over
low-dose TSEBT alone in participants with mycosis fungoides (MF)
Treatment in this study is TSEBT +/- vorinostat, with participants stratified by MF stage.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cutaneous Lymphoma Coordinator, 650-421-6370.
Lead Sponsor
Stanford Investigators
View full details
-
Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)
Not Recruiting
More
For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using
cells from a healthy donor represents potentially curative treatment. In these individuals,
cure is possible because transplantation of healthy donor immune cells can fight the lymphoma
in the patient. The goal of this work is to test a strategy that activates the healthy donor
immune cells so that they more effectively fight lymphoma and can result in an increased cure
rate for these patients. Our group has previously studied CpG, an immune activating
medication, in patients with lymphoma and demonstrated modest anti-tumor responses. We now
have a more potent form of CpG which we intend to test to see if it will better activate the
donor immune cells and result in shrinkage of tumor throughout the entire body, not just at
the injected site.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Not Recruiting
More
The purpose of this study is to compare the progression free survival of KW-0761 versus
vorinostat for subjects with relapsed or refractory CTCL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Illisha Rajasansi, 650-421-1397.
Stanford Investigators
View full details
-
Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma
Not Recruiting
More
To assess the safety and tolerability of escalating doses of SD-101 in combination with
localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell
lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kathleen McDonald, 650-725-8589.
Stanford Investigators
View full details
-
Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Not Recruiting
More
This study is designed to determine the recommended dose, safety, pharmacokinetics, and early
efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or
refractory CTCL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cutaneous Lymphoma Coordinator, 6504216370.
Stanford Investigators
View full details
-
Forodesine in the Treatment of Cutaneous T-Cell Lymphoma
Not Recruiting
More
This is a Phase II, non-randomized, open-label, single-arm trial that will be conducted at up
to 50 sites in North America, Europe and Australia. This study is designed to assess
objective response (OR) [complete response (CR) or partial response (PR)] in subjects with
cutaneous manifestations of CTCL with a requirement for maintenance of such objective
response for at least 28 days in subjects with stage IIB, III, and IVA CTCL. Additionally,
this study will evaluate the safety and tolerability of CTCL subjects Stages IB, IIA, IIB,
III, or IVA treated with oral forodesine.
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
-
Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma
Not Recruiting
More
This study is being conducted to identify how much and how often pralatrexate, given with
vitamin B12 and folic acid, can be given safely to patients with cutaneous T-cell lymphoma
(CTCL) that has relapsed (returned after responding to previous treatment) or is refractory
(has not responded to previous treatment). It is also being conducted to get information on
whether or not pralatrexate is effective in treating relapsed or refractory CTCL.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cameron Harrison, 6507217186.
Stanford Investigators
View full details
-
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides
Not Recruiting
More
This study will evaluate the efficacy, tolerability and safety of the topical application of
mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
-
Phase I/II Study of Intratumoral Injection of CPG 7909, a TLR9 Agonist, Combined With Local Radiation for Patients With Recurrent Mycosis Fungoides.
Not Recruiting
More
This is a single institution phase I / II trial to evaluate the safety and efficacy of
intratumoral CpG injections combined with local radiation in patients with mycosis fungoides.
Patients will receive low-dose radiotherapy to a single tumor site on days 1 and 2 (2 Gy each
day). CpG injections will be administered into the same tumor site within 24 hours before or
24 hours after each radiation treatment. Weekly doses of (intratumoral or peritumoral
injections) CpG will be then administered subcutaneously in the region of previous injections
for 23 additional doses. The total treatment duration is 24 weeks.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mayita Romero, 6507256452.
Lead Sponsor
Stanford Investigators
View full details
-
A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL)
Not Recruiting
More
GPI-04-0001 was a Phase II, non-randomized, open label, single arm study that was conducted
at approximately 30 sites, primarily in the United States, Europe and Russia. It assessed the
efficacy, safety, and tolerability of romidepsin as a treatment for cutaneous T-cell lymphoma
(CTCL). Study patients (pts) received romidepsin in a dose of 14 mg/m^2 intravenously over 4
hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles
although pts who showed an objective response or stable disease could continue to receive
therapy, at the discretion of the investigator, until disease progression or another
withdrawal criterion was met.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sunil Arani Reddy, 6507361234.
Stanford Investigators
View full details
-
CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas
Not Recruiting
More
Brief summary TBD
Stanford is currently not accepting patients for this trial.
For more information, please contact Cameron Harrison, 6507217186.
Stanford Investigators
View full details
-
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
More
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 650-725-1647.
Lead Sponsor
Stanford Investigators
View full details
-
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
Not Recruiting
More
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly
patients with advanced stage MDS and MPD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Not Recruiting
More
The purpose of the study is to assess the response rate of patients with relapsed or
refractory low-grade or transformed low-grade, CD20-positive, B-cell non-Hodgkin's lymphoma
to Iodine-131 (I-131) tositumomab (Bexxar) therapy plus local palliative radiation therapy
(XRT).
Stanford is currently not accepting patients for this trial.
For more information, please contact Lucy Schoen, 6507251718.
Lead Sponsor
Stanford Investigators
View full details
-
Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary Syndrome
Not Recruiting
More
RATIONALE: Lenalidomide may stop the growth of mycosis fungoides/Sezary syndrome by blocking
blood flow to the cancer.
PURPOSE: This phase II trial is studying how well lenalidomide works in treating patients
with relapsed mycosis fungoides/Sezary syndrome.
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
-
Rituximab in Treating Patients With Hodgkin's Lymphoma
Not Recruiting
More
Phase 2 trial to study the effectiveness of rituximab in treating patients who have
lymphocyte-predominant Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Daadi, 6507256456.
Stanford Investigators
View full details
-
Study of Oral LBH589 in Adult Participants With Refractory/Resistant Cutaneous T-Cell Lymphoma (CTCL)
Not Recruiting
More
This study evaluated the safety and efficacy of LBH589B in adult participants with
refractory/resistant Cutaneous T-Cell Lymphoma and prior Histone Deacetylase (HDAC) inhibitor
therapy.
Stanford is currently not accepting patients for this trial.
For more information, please contact Natalie Viakhireva, 6507238949.
Stanford Investigators
View full details
